PMID- 37000300
OWN - NLM
STAT- MEDLINE
DCOM- 20230522
LR  - 20230522
IS  - 1432-5233 (Electronic)
IS  - 0940-5429 (Print)
IS  - 0940-5429 (Linking)
VI  - 60
IP  - 7
DP  - 2023 Jul
TI  - Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 
      inhibitors on new-onset depression: a propensity score-matched study in Hong 
      Kong.
PG  - 917-927
LID - 10.1007/s00592-023-02063-6 [doi]
AB  - INTRODUCTION: The risk of new onset depression associated with sodium-glucose 
      co-transporter 2 inhibitor (SGLT2I) use in patients with type 2 diabetes mellitus 
      (T2DM) remains unclear. This study investigated the risk of new onset depression 
      between SGLT2I and dipeptidyl peptidase 4 inhibitor (DPP4I) users. METHODS: This 
      was a population-based cohort study of T2DM patients in Hong Kong between January 
      1st, 2015, and December 31st, 2019. T2DM patients over 18 with either SGLT2I or 
      DPP4I use were included. 1:1 propensity-score matching using the 
      nearest-neighbour method was conducted based on demographics, past comorbidities 
      and non-DPP4I/SGLT2I medication use. Cox regression analysis models were used to 
      identify significant predictors for new onset depression. RESULTS: The study 
      cohort included a total of 18,309 SGLT2I users and 37,269 DPP4I users (55.57% 
      male, mean age: 63.5 +/- 12.9 years) with a median follow-up duration of 5.56 (IQR: 
      5.23-5.8) years. After propensity score matching, SGLT2I use was associated with 
      a lower risk of new onset depression compared to DPP4I use (HR: 0.52, 95% CI: 
      [0.35, 0.77], P = 0.0011). These findings were confirmed by Cox multivariable 
      analysis and sensitive analyses. CONCLUSION: SGLT2I use is associated with 
      significantly lower risk of depression compared to DPP4 use in T2DM patients 
      using propensity score matching and Cox regression analyses.
CI  - (c) 2023. The Author(s).
FAU - Mui, Jonathan V
AU  - Mui JV
AD  - Diabetes Research Unit, Cardiovascular Analytics Group, Hong Kong, China.
FAU - Li, Lifang
AU  - Li L
AD  - Department of Biostatistics and Health Informatics, Institute of Psychiatry, 
      Psychology and Neuroscience, King's College London, London, UK.
FAU - Chou, Oscar Hou In
AU  - Chou OHI
AUID- ORCID: 0000-0001-7058-4708
AD  - Diabetes Research Unit, Cardiovascular Analytics Group, Hong Kong, China.
AD  - Department of Medicine, The University of Hong Kong, Hong Kong, China.
FAU - Azfar, Nida
AU  - Azfar N
AD  - Diabetes Research Unit, Cardiovascular Analytics Group, Hong Kong, China.
FAU - Lee, Athena
AU  - Lee A
AD  - Diabetes Research Unit, Cardiovascular Analytics Group, Hong Kong, China.
AD  - Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong 
      Kong, China.
FAU - Hui, Jeremy
AU  - Hui J
AD  - Diabetes Research Unit, Cardiovascular Analytics Group, Hong Kong, China.
AD  - Department of Medicine, The University of Hong Kong, Hong Kong, China.
FAU - Lee, Sharen
AU  - Lee S
AD  - Diabetes Research Unit, Cardiovascular Analytics Group, Hong Kong, China.
FAU - Tse, Gary
AU  - Tse G
AD  - Diabetes Research Unit, Cardiovascular Analytics Group, Hong Kong, China. 
      gary.tse@kmms.ac.uk.
AD  - Department of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, 
      China. gary.tse@kmms.ac.uk.
AD  - Kent and Medway Medical School, Canterbury, UK. gary.tse@kmms.ac.uk.
AD  - School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong 
      Kong, China. gary.tse@kmms.ac.uk.
AD  - Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical 
      University, Tianjin, 300211, China. gary.tse@kmms.ac.uk.
FAU - Zhou, Jiandong
AU  - Zhou J
AD  - Nuffield Department of Medicine, University of Oxford, Oxford, UK. 
      jiandong.zhou@ndm.ox.ac.uk.
LA  - eng
GR  - 72042018/National Natural Science Foundation of China/
GR  - T32-102/14N/Theme-Based Research Scheme of the Research Grants Council of Hong 
      Kong/
PT  - Journal Article
DEP - 20230331
PL  - Germany
TA  - Acta Diabetol
JT  - Acta diabetologica
JID - 9200299
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - EC 3.4.14.- (Dipeptidyl-Peptidases and Tripeptidyl-Peptidases)
RN  - IY9XDZ35W2 (Glucose)
RN  - 9NEZ333N27 (Sodium)
SB  - IM
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Aged
MH  - Female
MH  - *Dipeptidyl-Peptidase IV Inhibitors/adverse effects
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology
MH  - Cohort Studies
MH  - Propensity Score
MH  - Hong Kong/epidemiology
MH  - Depression/drug therapy/epidemiology
MH  - Hypoglycemic Agents/therapeutic use
MH  - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
MH  - Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/therapeutic use
MH  - Glucose
MH  - Sodium/therapeutic use
MH  - Retrospective Studies
PMC - PMC10198893
OTO - NOTNLM
OT  - Anti-diabetic medication
OT  - DPP4 inhibitor
OT  - Depression
OT  - SGLT2 inhibitor
OT  - Type 2 diabetes
COIS- The authors have no relevant financial or non-financial interests to disclose. 
      All authors certify that they have no affiliations with or involvement in any 
      organization or entity with any financial interest or non-financial interest in 
      the subject matter or materials discussed in this manuscript.
EDAT- 2023/04/01 06:00
MHDA- 2023/05/22 06:43
PMCR- 2023/03/31
CRDT- 2023/03/31 11:17
PHST- 2022/10/29 00:00 [received]
PHST- 2023/02/24 00:00 [accepted]
PHST- 2023/05/22 06:43 [medline]
PHST- 2023/04/01 06:00 [pubmed]
PHST- 2023/03/31 11:17 [entrez]
PHST- 2023/03/31 00:00 [pmc-release]
AID - 10.1007/s00592-023-02063-6 [pii]
AID - 2063 [pii]
AID - 10.1007/s00592-023-02063-6 [doi]
PST - ppublish
SO  - Acta Diabetol. 2023 Jul;60(7):917-927. doi: 10.1007/s00592-023-02063-6. Epub 2023 
      Mar 31.